Clasificación en acciones
#32729
NuCana plc is a clinical-stage biopharmaceutical firm dedicated to pioneering... NuCana plc is a clinical-stage biopharmaceutical firm dedicated to pioneering advanced therapies for oncology. Its innovative product pipeline is underpinned by a proprietary ProTide technology platform. Among its key drug candidates, Acelarin is progressing through multiple clinical evaluations: a Phase I study for advanced solid tumors, Phase Ib trials for both recurrent ovarian cancer and biliary tract cancer, a Phase II trial targeting platinum-resistant ovarian cancer, and a pivotal Phase III trial for pancreatic cancer. NuCana is also developing NUC-3373, a ProTide derivative of 5-fluorouracil’s active anti-cancer metabolite. This compound is currently in a Phase I study for advanced solid tumors and a Phase Ib/2 trial for advanced colorectal cancer. Additionally, NUC-7738, a nucleoside analog, is undergoing Phase 1/2 clinical assessment for both advanced solid and hematological malignancies. To support its ProTide technology development, the company maintains research, collaboration, and licensing agreements with Cardiff University and University College Cardiff Consultants Ltd., covering the design, synthesis, characterization, and assessment of these compounds. Further collaborative and licensing arrangements are in place with Cardiff ProTides Ltd. Established in 1997, the company operated as NuCana BioMed Limited before rebranding to NuCana plc in August 2017. Its corporate headquarters are located in Edinburgh, United Kingdom.
Capitalización bursátil
$9.44M
Comercio NuCana plc (NCNA)
Precio NCNA con Capital del mercado a B
Capitalización de mercado de NuCana plc(NCNA)
Capitalización bursátil: $9.44M
A fecha de August 2026, NuCana plc tiene una capitalización de mercado de $9.44M. Esto convierte a NuCana plc en la 32729th empresa más valiosa del mundo por capitalización bursátil, según nuestros datos. La capitalización bursátil es el valor total de mercado de las acciones en circulación de una empresa que cotiza en bolsa y se utiliza comúnmente para medir su valor.
Historial de capitalización de mercado de NuCana plc desde 2017 hasta 2026
NCNA en comparación con los más populares 5 títulos stocks
| Precio por NCNA |
|
Activo B |
Capital del mercado en B |
Resultados |
|
|
|
|
$5.466T
|
+57,886,607.31%
|
|
|
|
|
$4.487T
|
+47,524,168.93%
|
|
|
|
|
$4.141T
|
+43,852,371.24%
|
|
|
|
|
$3.566T
|
+37,765,906.50%
|
|
|
|
|
$2.794T
|
+29,589,070.71%
|
